Dr Satu Vainikka, CEO commented:

"I am delighted that we are now launching our Chlamydia self-testing product into the UK and Irish markets. With Chlamydia being diagnosed as the fastest growing sexually transmitted disease at the moment, our self-testing pack, as an affordable, easy -to-use and rapid indicator of the presence or absence of the Chlamydia bacterium has the potential to become a first line test against Chlamydia. With the disease having the potential to affect fertility in both sexes, I particularly urge young people looking to start a family to test themselves early. Early detection will mean early intervention and thinking that there is not a problem is just not thinking."

Broker Hybridan was positive about the launch, stating that ValiRx remains far from fully valued at these levels.

We like the model of product on the market generating revenues in the test kits and the more blue sky upside that its proprietary drug development programmes provide in the technology platform, said Hybridan.

Last month, ValiRx completed the sale of its Belgian diagnostic development business, ValiBIO SA, to Singapore Volition Pte Ltd, having received all the funds it was due.

ValiRx continues to retain its significant shareholding in Volition and in the future upside value and growth of the business and integration between the companies is progressing well

http://www.proactiveinvestors.co.uk/companies/news/25504/valirx-aim-stock-out-of-the-doldrums-25504.html

from the other side....

'Broker note due out today / next week.

HPV tester due for launch early/mid 2011 - remember the spike from the Chlamydia tester?

AGM June 2011 - always a bit of movement on anticpation, also this year we have revenue streams coming forward!

GENEice pre-clinical results close 2011 - significance on a par with SAR imo

3.3M cash in the bank

Novel and commercially - focussed business model and BoD looking to improve shareholder value short term

10% rise over last 2 days

Currently sitting just above share issue effectively underwritten at .6

tiny market cap primed for growth

new driven.

these are just some of the +ives in my opinion. If you're nervous, average down, wait for news, set an RNS text alert, then come back then and sell-off when you've made some , which you will do. this company is not going to dissapear - so what's the panic?'

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=10808177

from jan but worth a reminder............

ValiRxSPECULATIVE BUY 21/01/2011 Ben Jaglom
Reduce text size Decrease text size Increase text size Increase text size Print article Print Share this article Share Email article to a friend Email HPV testing and cancer technology developer ValiRX (VAL) is hoping to boost its lowly share price over the coming years.

The London-headquartered concern has two parts to its business. There is ValiPharma, which is developing the GeneICE technology, a way of putting on ice cancer cells and which was developed by Imperial College, London and Cancer Research Technology, the commercial arm of cancer charity Cancer Research.

In addition there is a clinical testing division, which under the brand SELFcheck sells tests for a range of conditions including the menopause, female Chlamydia and stomach ulcers, with the kits sold to a range of retailers as well as directly online.

It is also currently developing a test for the sexually transmitted Human Papilloma Virus (HPV) a virus that can cause genital warts and cervical cancer.

Having come to AIM in 2006 the venture is led by Satu Vinikka, the Finnish CEO who was previously the CEO of Cronos Therapeutics, the spin out from Imperial College that was purchased by ValiRX in 2006.

Last December saw ValiRx provide an update on its progress with Eurostars. Eurostars is a grant scheme that provides funding for companies in the EU. ValiRx had received 1.2m (1m) in funding for its cancer drug GeneICE and the update came eighteen months into the deal, with ValiRx having now submitted the progress report necessary to obtain the next stage in funding.

House broker Hybridan is forecasting a loss of 507,482 on a turnover of 95,869 for the year to 2010, with profits not expected until 2012 when the broker is pencilling in a maiden profit of 774,823 on turnover of 1.4m.

A tiny company with a correspondingly tiny share price, shares in ValiRx are certainly not for widows and orphans. However with a relatively diversified business split between its GeneICE programme and its testing division, we think as a speculative investment the shares are certainly worth a punt.

worth a look today?

apparently news expected from US cancer conf
appeared to go very well

bought in this morning...worth a punt I reckon...up a little already!

The directors of Sarantel Group (AIM: SLG), National Milk Records (PLUS: NMRP) and ValiRx (AIM: VAL) will be presenting: Wednesday the 18th May 2011, Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB (Charles Suite)

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception.

FREE registration - http://www.proactiveinvestors.co.uk/register/event_details/110

This event is suitable for the following:
Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

The event is not suitable for people pursuing commercial opportunities.

If you have any problems registering or queries please email events@proactiveinvestors.com.

Gonna buy more....this will do good in a year or two (imho)

important rns today - eu patent won can go into production ref cancer treatment

:-))

ValiRx shares soar as cancer test gets EU patent

8:40 am by Jamie Ashcroft ValiRx says the test enables the detection of cancer cells at the stage where chromosomal changes have just taken place and tumor development is about to start. Shares in life science firm ValiRx (LON:VAL) shot up around 35 per cent in early deals after it was granted a new European patents for a cancer screening product.

The test is for a biomarker, called NAV3, which is part of an already ‘well-developed’ test kit. And with the patent being granted the company is now able to begin producing and marketing the product.

ValiRx says the cancer test enables the detection of cancer cells at a time when tumour development is about to start.

This is one of five patent family assets that were acquired last month.

"The granting of this latest patent by the European Patent Office further underpins our global geographic patent coverage,” said chief executive Dr Satu Vainikka.

“I believe, strongly vindicates our establishment of ValiFinn and our recent acquisition from Pharmatest of our Finnish biomarkers business, in this rapidly growing marketplace.”

ValiRx explained that sample kits have already been produced and trialled. Several scientific publications have endorsed the technology, it said.

Following the Pharmatest deal ValiRx now owns the patents and retains all commercial rights to each of the five patent family assets.

It said that it is currently in talks with potential production and clinical partners about these assets.

I hope you bought recently!

More sells than buys!
Do they have money to pay their staff?

They raised 3 million last year.

i did skinny cheers

ahoj - it appears more sells than buys but i was watching for a lot of the time and a high % of sells were in fact buys - stats totally skewed

markymar - yep 3mil was raised

very good news today

Been worth hanging onto for these past 18months after all! onward and upwards!

still waiting for the "onward and upwards!" to happen. have sold half to go into SCLP..but let's see what happens here also!

you are likely to need a degree of patience here - but rest of this year looks promising depends how high you set the bar though :-)))

Have a peek at the interview with Dr George Morris - Link